John C. Rhee

499 total citations
22 papers, 235 citations indexed

About

John C. Rhee is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, John C. Rhee has authored 22 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Molecular Biology and 4 papers in Hepatology. Recurrent topics in John C. Rhee's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). John C. Rhee is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). John C. Rhee collaborates with scholars based in United States, Poland and China. John C. Rhee's co-authors include Fadlo R. Khuri, Dong M. Shin, William L. Smith, Robert C. Osorio, Edward Chu, Robert W. Osorio, Jennifer Guy, Maha Boktour, Catherine Frenette and Nathan Bahary and has published in prestigious journals such as Journal of Clinical Oncology, Transplantation and The Oncologist.

In The Last Decade

John C. Rhee

21 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John C. Rhee United States 8 98 59 44 43 39 22 235
Fei Yin China 11 83 0.8× 115 1.9× 51 1.2× 18 0.4× 27 0.7× 28 265
Helena Degroote Belgium 11 66 0.7× 86 1.5× 91 2.1× 46 1.1× 94 2.4× 30 309
Atsutaka Masuda Japan 9 85 0.9× 142 2.4× 61 1.4× 27 0.6× 24 0.6× 19 279
Zhipeng Cao Australia 7 48 0.5× 110 1.9× 33 0.8× 28 0.7× 19 0.5× 17 247
Linghua Zhu China 9 34 0.3× 130 2.2× 43 1.0× 17 0.4× 44 1.1× 26 263
Jiandong Tong China 8 116 1.2× 159 2.7× 13 0.3× 24 0.6× 43 1.1× 10 297
Pierre–Olivier Schischmanoff France 5 45 0.5× 55 0.9× 51 1.2× 30 0.7× 6 0.2× 7 237
Kiyoyuki Kobayashi Japan 10 91 0.9× 162 2.7× 17 0.4× 55 1.3× 75 1.9× 19 293
Yutaka Takigawa Japan 7 107 1.1× 167 2.8× 51 1.2× 17 0.4× 58 1.5× 27 330
Hao Zeng China 8 60 0.6× 81 1.4× 54 1.2× 36 0.8× 18 0.5× 20 206

Countries citing papers authored by John C. Rhee

Since Specialization
Citations

This map shows the geographic impact of John C. Rhee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Rhee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Rhee more than expected).

Fields of papers citing papers by John C. Rhee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Rhee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Rhee. The network helps show where John C. Rhee may publish in the future.

Co-authorship network of co-authors of John C. Rhee

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Rhee. A scholar is included among the top collaborators of John C. Rhee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Rhee. John C. Rhee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Krishnamurthy, Anuradha, Hong Wang, John C. Rhee, et al.. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology. 95(1). 27–27. 4 indexed citations
2.
Jonassaint, Naudia, John C. Rhee, Dennis Hsu, et al.. (2025). Phase II trial of zanzalintinib (XL-092) in combination with durvalumab and tremelimumab in unresectable hepatocellular carcinoma (ZENOBIA).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations
3.
Wang, Hong, Terry Evans, James G. Herman, et al.. (2024). Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy. Clinical Lung Cancer. 26(1). 78–81. 1 indexed citations
4.
Şahin, İbrahim Halil, Turçin Saridogan, Rüveyda Ayasun, et al.. (2024). Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine. JCO Oncology Practice. 20(10). 1336–1347. 7 indexed citations
5.
Şahin, İbrahim Halil, Sakti Chakrabarti, Tullia C. Bruno, et al.. (2024). Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.. Journal of Clinical Oncology. 42(3_suppl). TPS238–TPS238.
6.
Gentzler, Ryan D., Liza C. Villaruz, John C. Rhee, et al.. (2023). Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist. 28(11). 1007–e1107. 10 indexed citations
7.
Sleiman, Joseph, Rhonda M. Brand, Reetesh K. Pai, et al.. (2023). Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways. Clinical Journal of Gastroenterology. 16(5). 680–684. 6 indexed citations
8.
Kuang, Chaoyuan, Yongseok Park, Ryan C. Augustin, et al.. (2022). Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis. Clinical Epigenetics. 14(1). 3–3. 42 indexed citations
9.
Villaruz, Liza C., Karen Kelly, Saiama N. Waqar, et al.. (2022). NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 3012–3012. 4 indexed citations
10.
Maguire, William F., John C. Schmitz, Shaoyu Wu, et al.. (2021). Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 88(4). 643–654. 4 indexed citations
11.
Kuang, Chaoyuan, Yongseok Park, Nathan Bahary, et al.. (2020). Biomarker analysis for UPCI 14-118: Phase II study of pembrolizumab in combination with azacitidine in patients with refractory metastatic colorectal cancer.. Journal of Clinical Oncology. 38(4_suppl). 173–173. 2 indexed citations
12.
Peters, Mary Linton B., Randall E. Brand, Erkut Borazanci, et al.. (2017). Germline genetic testing in unselected pancreatic ductal adenocarcinoma (PDAC) patients.. Journal of Clinical Oncology. 35(15_suppl). 1501–1501. 1 indexed citations
13.
Lee, James J., Weijing Sun, Nathan Bahary, et al.. (2017). Phase 2 study of pembrolizumab in combination with azacitidine in subjects with metastatic colorectal cancer.. Journal of Clinical Oncology. 35(15_suppl). 3054–3054. 26 indexed citations
14.
Donnenberg, Vera S., Maja Mandić, John C. Rhee, et al.. (2017). Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Biologics. The Journal of Clinical Pharmacology. 57(8). 947–955. 3 indexed citations
15.
Frenette, Catherine, Robert C. Osorio, Maha Boktour, et al.. (2014). Conventional TACE and Drug-Eluting Bead TACE as Locoregional Therapy Before Orthotopic Liver Transplantation. Transplantation. 98(7). 781–787. 36 indexed citations
16.
Rhee, John C., et al.. (2005). The Effects of Hepatic Artery Chemotherapy on Viral Hepatitis in Patients With Hepatocellular Carcinoma. Digestive Diseases and Sciences. 50(2). 331–335. 12 indexed citations
17.
Rhee, John C., et al.. (2005). Uncommon Presentations of Some Common Malignancies. Journal of Clinical Oncology. 23(6). 1315–1317. 7 indexed citations
18.
Rhee, John C., Fadlo R. Khuri, & Dong M. Shin. (2004). Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs. 9(1). 91–104. 3 indexed citations
19.
Rhee, John C., Fadlo R. Khuri, & Dong M. Shin. (2004). Advances in Chemoprevention of Head and Neck Cancer. The Oncologist. 9(3). 302–311. 28 indexed citations
20.
Rhee, John C., et al.. (1994). Plasma Levels of Peptide YY Correlate with Cisplatin-induced Emesis in Dogs. Journal of Pharmacy and Pharmacology. 46(7). 553–557. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fei Yin Breakdown of academic impact, for papers by Helena Degroote Breakdown of academic impact, for papers by Atsutaka Masuda Breakdown of academic impact, for papers by Zhipeng Cao Breakdown of academic impact, for papers by Linghua Zhu Breakdown of academic impact, for papers by Jiandong Tong Breakdown of academic impact, for papers by Pierre–Olivier Schischmanoff Breakdown of academic impact, for papers by Kiyoyuki Kobayashi Breakdown of academic impact, for papers by Yutaka Takigawa Breakdown of academic impact, for papers by Hao Zeng
Rankless by CCL
2026